Valuation check: XGN's profit margin is -25.14%, below the Healthcare sector average of 17.63%.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
The latest profit margin for XGN is -25.14% as of September 2026. That compares with -29.94% in the prior-year period — up 16.0% year over year. That is below the Healthcare sector average of 17.63%. Investors often review this figure alongside Exagen's historical trend and sector peers before judging valuation or financial health.
Over the past year, XGN's profit margin moved from -29.94% to -25.14% — a 16.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Exagen's valuation or profitability profile.
Against Healthcare companies, XGN currently prints -25.14% for profit margin, while the sector average sits near 17.63%. That is roughly 242.6% below the sector mean. Large gaps often invite a closer look at Exagen's growth, margins, and balance sheet.
Profit Margin shows how effectively Exagen converts resources into returns. At -25.14%, XGN may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -29.94% in the prior-year period — up 16.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting XGN's profit margin (-25.14%), review year-over-year change from -29.94%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.